Descovy (Emtricitabine/Tenofovir Alafenamide) for HIV: Complete Guide
Descovy (emtricitabine 200 mg / tenofovir alafenamide 25 mg) is a once-daily single-tablet regimen for HIV-1 treatment in adults and adolescents ≥35 kg. It combines two NRTIs with improved renal/bone safety vs. tenofovir disoproxil fumarate (TDF).
Indications
- HIV-1 treatment: In combination with other antiretrovirals (e.g., integrase inhibitors, NNRTIs, boosted PIs).
- HIV-1 PrEP: Descovy is not approved for PrEP (use Truvada or Apretude).
Key Advantages vs. TDF-Containing Regimens
- Renal safety: 90% lower tenofovir plasma exposure → less proximal tubulopathy, Fanconi syndrome, eGFR decline.
- Bone safety: Less BMD loss at spine/hip; fewer fractures in trials.
- Smaller tablet: Better adherence potential.
Dosing & Administration
- One tablet daily, with or without food.
- No dose adjustment for eGFR ≥30 mL/min.
- Not recommended if eGFR <30 (insufficient data).
- Take consistently; missed doses → resistance risk.
Common Side Effects (≥2%)
- Nausea, diarrhea, headache, fatigue, abnormal dreams, rash.
- Weight gain (class effect with INSTI combinations).
Serious Risks
- Lactic acidosis + severe hepatomegaly with steatosis: Rare, life-threatening. Higher risk in females, obesity, prolonged NRTI exposure.
- Renal impairment: Monitor eGFR, UACR, serum phosphate periodically.
- HBV flare: If co-infected, discontinuing Descovy can cause severe hepatitis. Test for HBV before initiation.
- IRIS: Immune reconstitution inflammatory syndrome after ART initiation.
Major Drug Interactions
- Do not co-administer with: Other tenofovir/emtricitabine products, adefovir, didanosine.
- Caution with: NSAIDs, acyclovir, valacyclovir, ganciclovir, valganciclovir, aminoglycosides (additive nephrotoxicity).
- CYP3A4/P-gp interactions: TAF is a substrate; strong inducers (rifampin, carbamazepine, St. John's wort) ↓ levels. Strong inhibitors generally safe but monitor.
Monitoring
- HIV-1 RNA q3–6mo (goal: undetectable <50 copies/mL).
- CD4 count q3–6mo initially.
- eGFR, UACR, serum phosphate q6–12mo.
- BMD (DEXA) if risk factors.
- Fasting glucose, lipids annually.
Special Populations
- Pregnancy: Sufficient data support use; preferred NRTI backbone per DHHS guidelines.
- Adolescents ≥35 kg: Approved.
- Hepatic impairment: No dose adjustment (Child-Pugh A/B); avoid Child-Pugh C.
Cost & Access
- Wholesale: ~$2,000–$2,200/month.
- Gilead Advancing Access, copay cards, patient assistance programs.
- Generic entry expected post-2025 (patent landscape complex).
Descovy is a preferred NRTI backbone for HIV treatment, offering superior renal/bone safety. Not for PrEP. Requires combination therapy and regular monitoring.
HIV & AIDS - Related Articles
- Why an HIV Vaccine Remains Elusive: The Scientific Hurdles
- HIV Blood Tests: ELISA and Western Blot Explained
- HIV Transmission Myths: Can You Get HIV from a Plaster on the Floor?
- HIV Symptoms by Stage: Acute, Latency & AIDS – What to Expect
- HIV Prevalence in the Democratic Republic of Congo: 1.2% Among Adults (2020)
- Protease: Understanding Its Role in Digestion & Health
- Understanding HIV Transmission: Routes, Fluids, and Prevention Pillars
